Newsroom - Page 10

The first patient has been treated with ruxolitinib (Jakafi), by Incyte Corporation, for steroid-refractory acute graft-versus-host disease, as part of the REACH-1 phase 2 trial. The trial is evaluating ruxolitinib in combination with corticosteroids.
A look at value-based insurance design, and how it provides a way to reduce financial barriers to care for people with chronic conditions.
The groups represent nearly 400,000 practitioners on the front lines of primary care for families, women, and children.
Research on the role of community health workers shows that they can help patients manage their hypertension, in part by addressing barriers to medication adherence.
The American College of Physicians' oral medication guideline for treating type 2 diabetes is the first update since 2012, and it reflects many new medications that have received FDA approval since that time.
What we're reading, January 3, 2017: Colorado's Affordable Care Act exchange misused more than $9 million in federal funds; an over-the-counter birth control may be coming to the United States; and returning health data to patients could reduce health record breaches.
What we're reading, January 2, 2017: drug makers are taking a cautious approach to off-label promotion; Republicans eye changes to Medicaid under Trump administration; and the impact of geography on health.
As 2016 drew to a close, The American Journal of Managed Care (AJMC)® polled readers on what was, in their opinion, the biggest healthcare story of the year. Runners-up included drug pricing drama, Medicare policy announcements, and more, but the top answer by far was the news story that sent shockwaves throughout the healthcare industry and around the world.
Compendia
COPD Compendium
Diabetes Compendium
MACRA Compendium
Oncology Compendium
Rare Disease Compendium
Reimbursement Compendium
Know Your News
HF Compendium
$AD300x250BB$